# A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

> **NCT04258995** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 151 (actual)

## Conditions studied

- Group B Streptococcal Infections

## Interventions

- **BIOLOGICAL:** Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)

## Key facts

- **NCT ID:** NCT04258995
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-09-15
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258995, "A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04258995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*